Select Publications
Book Chapters
2024, 'WHAT ARE THE RISKS OF BIOLOGIC THERAPIES AND HOW DO YOU COMMUNICATE THEM TO PATIENTS?', in Curbside Consultation in IBD: 49 Clinical Questions, pp. 115 - 121, http://dx.doi.org/10.1201/9781003523567-23
,Journal articles
2025, 'On being on the same page: Predictors of gastroenterologist-patient misalignment in inflammatory bowel disease', Patient Education and Counseling, 130, http://dx.doi.org/10.1016/j.pec.2024.108487
,2024, 'Is the European Crohn’s and Colitis organisation (ECCO) e-guide an acceptable and feasible tool for increasing gastroenterologists’ guideline adherence? A mixed methods evaluation', BMC Medical Education, 24, http://dx.doi.org/10.1186/s12909-024-05540-w
,2024, 'Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.', Intest Res, http://dx.doi.org/10.5217/ir.2024.00089
,2024, 'Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial', Clinical Gastroenterology and Hepatology, 22, pp. 2299 - 2308.e5, http://dx.doi.org/10.1016/j.cgh.2024.04.019
,2024, 'Dietary Emulsifier Exposure in People with Inflammatory Bowel Disease Compared with Healthy Controls: Is There a Cause for Concern?', Inflammatory Bowel Diseases, 30, pp. 1241 - 1250, http://dx.doi.org/10.1093/ibd/izad318
,2024, 'Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial', BMJ Open, 14, http://dx.doi.org/10.1136/bmjopen-2023-081787
,2024, 'Preferred definitive surgical management of Crohn's perianal fistulas and factors influencing surgical decision making in Australia and New Zealand', ANZ Journal of Surgery, 94, pp. 14 - 16, http://dx.doi.org/10.1111/ans.18640
,2024, 'P1005 Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1818 - i1818, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1135
,2024, 'P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1829 - i1829, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1142
,2024, 'P1030 Inflammatory Bowel Disease helpline contact trends in a real-world Australasian cohort: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1858 - i1859, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1160
,2024, 'P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i2023 - i2023, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1259
,2024, 'P286 Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i657 - i657, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0416
,2024, 'P462 The burden of mental health disease in people with inflammatory bowel disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i930 - i930, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0592
,2024, 'P529 Assessing patient-perceived burden of disease in Crohn’s disease: a novel scoring approach in a real-world Australasian cohort', Journal of Crohn's and Colitis, 18, pp. i1042 - i1044, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0659
,2024, 'P547 Improved clinical and radiologic healing of Crohn’s perianal fistulas using a novel coordinated care model optimising medical and surgical treatments: A prospective real-world observational study', Journal of Crohn's and Colitis, 18, pp. i1077 - i1078, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0677
,2024, 'P654 Assessing patient-perceived burden of disease in Ulcerative Colitis: a novel scoring approach in a real-world Australasian cohort', Journal of Crohn's and Colitis, 18, pp. i1246 - i1248, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0784
,2024, 'P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis', Journal of Crohn's and Colitis, 18, pp. i1583 - i1583, http://dx.doi.org/10.1093/ecco-jcc/jjad212.0984
,2024, 'P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program', Journal of Crohn's and Colitis, 18, pp. i1622 - i1623, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1010
,2024, 'P940 A glance into paediatric Inflammatory Bowel Disease in Australasia – Crohn’s Colitis Cure (CCC) data insights program', Journal of Crohn's and Colitis, 18, pp. i1711 - i1712, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1070
,2024, 'P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program', Journal of Crohn's and Colitis, 18, pp. i1742 - i1742, http://dx.doi.org/10.1093/ecco-jcc/jjad212.1089
,2024, 'Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: Advances and future directions', eGastroenterology, 2, http://dx.doi.org/10.1136/egastro-2023-100006
,2024, 'Treatment outcomes of mild to moderate Clostridioides difficile infection in inflammatory bowel disease: an Australian experience', Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16545
,2024, '903 TOFACITINIB DEMONSTRATES PRELIMINARY EFFICACY IN INDUCTION OF REMISSION IN CHRONIC POUCHITIS', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)00988-0
,2024, 'High Technical Success Rate of Endoscopic Balloon Dilatation Reduces Surgical Requirement for Patients With Stricturing Crohn’s Disease', GastroHep, 2024, http://dx.doi.org/10.1155/2024/3686618
,2024, 'Mo1817 IMPROVED CLINICAL AND RADIOLOGIC HEALING OF CROHN'S PERIANAL FISTULAS USING A NOVEL COORDINATED CARE MODEL OPTIMISING MEDICAL AND SURGICAL TREATMENTS: A PROSPECTIVE REAL-WORLD OBSERVATIONAL STUDY', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03056-7
,2024, 'Mo1833 DOSE ESCALATED USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03072-5
,2024, 'Mo1834 DOSE ESCALATED VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03073-7
,2024, 'Mo1835 DOSE ESCALATED INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 1135, http://dx.doi.org/10.1016/s0016-5085(24)03074-9
,2024, 'Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, pp. S - 839, http://dx.doi.org/10.1016/s0016-5085(24)02405-3
,2024, 'Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)02438-7
,2024, 'Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM', Gastroenterology, 166, http://dx.doi.org/10.1016/s0016-5085(24)03792-2
,2023, 'Co-design and Consultation Ensure Consumer Needs Are Met: Building an eHealth Platform for Children with Inflammatory Bowel Disease', Digestive Diseases and Sciences, 68, pp. 4368 - 4380, http://dx.doi.org/10.1007/s10620-023-08146-2
,2023, 'The Evolving Role of Technology in Delivering Patient-centric, Empowered Health Care in Inflammatory Bowel Disease: Patient Experience Using Crohn's Colitis Care e-Health Consumer Platform', Inflammatory Bowel Diseases, 29, pp. 1510 - 1511, http://dx.doi.org/10.1093/ibd/izad148
,2023, 'Adolescents and young adults communicating with gastroenterologists: Variation in inflammatory bowel disease clinical communication', International Journal of Adolescent Medicine and Health, 35, pp. 347 - 361, http://dx.doi.org/10.1515/ijamh-2023-0078
,2023, 'Clinician Adherence to Inflammatory Bowel Disease Guidelines: Results of a Qualitative Study of Barriers and Enablers', Crohn's and Colitis 360, 5, http://dx.doi.org/10.1093/crocol/otac018
,2023, 'Health Communication Research Informs Inflammatory Bowel Disease Practice and Research: A Narrative Review', Crohn's and Colitis 360, 5, http://dx.doi.org/10.1093/crocol/otad021
,2023, 'Letter: expanding the role for decision aids in IBD into pregnancy-related topics', Alimentary Pharmacology and Therapeutics, 58, pp. 141 - 142, http://dx.doi.org/10.1111/apt.17545
,2023, 'Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease', Digestive Diseases and Sciences, 68, pp. 889 - 896, http://dx.doi.org/10.1007/s10620-022-07556-y
,2023, 'Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial', The Lancet Gastroenterology and Hepatology, 8, pp. 215 - 227, http://dx.doi.org/10.1016/S2468-1253(22)00385-5
,2023, 'An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis', Journal of Crohn's and Colitis, 17, pp. 277 - 288, http://dx.doi.org/10.1093/ecco-jcc/jjac121
,2023, 'Assessing the Relationship between the Gut Microbiota and Inflammatory Bowel Disease Therapeutics: A Systematic Review', Pathogens, 12, http://dx.doi.org/10.3390/pathogens12020262
,2023, 'Colonic Epstein-Barr Virus-Associated Mucocutaneous Ulcer Associated With Ulcerative Colitis', ACG CASE REPORTS JOURNAL, 10, http://dx.doi.org/10.14309/crj.0000000000000978
,2023, 'P185 Global perception of normal life by healthcare professionals and IBD patients: mind the gap', Journal of Crohn's and Colitis, 17, pp. i337 - i339, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0315
,2023, 'P340 Issues on implementing treat-to-target approach in Asia Pacific, Middle East and Africa: Reality, gaps, and way forward -APMA IBD Coalition', Journal of Crohn's and Colitis, 17, pp. i476 - i478, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0470
,2023, 'P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial', Journal of Crohn's and Colitis, 17, pp. i542 - i543, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0543
,2023, 'P523 Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn’s Colitis Care (CCCare): A real world observational study.', Journal of Crohn's and Colitis, 17, pp. i650 - i651, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0653
,2023, 'P538 Suboptimal disease control is common in patients with Crohn’s perianal fistulas with capacity to optimise medical and surgical treatment in real-world experience: A cross-sectional analysis of baseline disease characteristics in the FINESS study', Journal of Crohn's and Colitis, 17, pp. i666 - i666, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0668
,2023, 'P550 Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years', Journal of Crohn's and Colitis, 17, pp. i678 - i680, http://dx.doi.org/10.1093/ecco-jcc/jjac190.0680
,2023, 'Integration of mental health and quality of life screening tools in an inflammatory bowel disease-specific electronic medical record (Crohn Colitis Care): process and early outcomes', Internal Medicine Journal, 53, pp. 136 - 139, http://dx.doi.org/10.1111/imj.15989
,